Secondary analysis comparing BETAMI-DANBLOCK trial participants (n=5574) with 20 804 registry MI patients with LVEF ≥40%: 3-year death or MI was 12.0% in the registry vs 7.7% and 7.8% in the trials; beta-blocker effect was similar after weighting to registry.
Secondary analysisn = 26,378
Kristensen et al. Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population